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Abstract
Background: Medical research to improve health care faces a major problem in the relatively
limited availability of adequately annotated and collected biospecimens. This limitation is creating a
growing gap between the pace of scientific advances and successful exploitation of this knowledge.
Biobanks are an important conduit for transfer of biospecimens (tissues, blood, body fluids) and
related health data to research. They have evolved outside of the historical source of tissue
biospecimens, clinical pathology archives. Research biobanks have developed advanced standards,
protocols, databases, and mechanisms to interface with researchers seeking biospecimens.
However, biobanks are often limited in their capacity and ability to ensure quality in the face of
increasing demand. Our strategy to enhance both capacity and quality in research biobanking is to
create a new framework that repatriates the activity of biospecimen accrual for biobanks to clinical
pathology.
Methods: The British Columbia (BC) BioLibrary is a framework to maximize the accrual of high-
quality, annotated biospecimens into biobanks. The BC BioLibrary design primarily encompasses:
1) specialized biospecimen collection units embedded within clinical pathology and linked to a
biospecimen distribution system that serves biobanks; 2) a systematic process to connect potential
donors with biobanks, and to connect biobanks with consented biospecimens; and 3)
interdisciplinary governance and oversight informed by public opinion.
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Results:  The BC BioLibrary has been embraced by biobanking leaders and translational
researchers throughout BC, across multiple health authorities, institutions, and disciplines. An
initial pilot network of three Biospecimen Collection Units has been successfully established. In
addition, two public deliberation events have been held to obtain input from the public on the
BioLibrary and on issues including consent, collection of biospecimens and governance.
Conclusion: The BC BioLibrary framework addresses common issues for clinical pathology,
biobanking, and translational research across multiple institutions and clinical and research
domains. We anticipate that our framework will lead to enhanced biospecimen accrual capacity and
quality, reduced competition between biobanks, and a transparent process for donors that
enhances public trust in biobanking.
Background
In the past decade, unprecedented progress has been
made in health research towards realizing the goal of per-
sonalized medicine guided by biomarkers and the ability
to match the right preventive or treatment with the right
patient, at the right time. Key to this progress has been the
various '-omics' platforms, as well as bioinformatics,
molecular imaging, drug discovery, and in the develop-
ment of animal models of human disease [1-3]. However,
there is now a disparity between the pace of scientific
advances and the successful utilization of this knowledge
for human benefit. This is partly due to the neglect of a
critical platform for this path to personalized medicine -
the process of securing biospecimens of the necessary
quality, capacity, and level of annotation, and that are
truly representative of diseased populations.
Biobanks
Biobanks are central to the process of collection of human
biospecimens for translational research and have contrib-
uted to numerous advancements in our understanding
and treatment of disease [3,4]. Biobanks are collections of
human biospecimens (tissues, blood and body fluids and
their derivatives collected for diagnosis and/or for
research projects) and their associated clinical and out-
come data. These biospecimens are typically obtained
from a subset of the public who become patients in the
health care system. These patients provide biospecimens
during clinic visits, diagnostic or therapeutic procedures,
or at autopsy. The biospecimens accrued by biobanks are
processed and preserved in a variety of ways to support
different clinical and research uses, including fixation,
freezing and live cell banking. Annotation encompasses
documentation of the biospecimen's composition, as well
as linkage to health data associated with the patient and
their condition, treatment and outcome. Processed and
annotated biospecimens are then released to researchers.
This typically occurs through selection of biospecimen
cohorts from the biobank database using specified criteria
to allow a specific research question to be addressed.
Biobanks range in design and user, from those whose pri-
mary focus is to support clinical health care (clinical
biobanks, including pathology archives) to those that
have evolved to primarily support research. Research
biobanks exist in many formats from population
biobanks to disease-focused biobanks. The latter include
informal biobanks associated with small and large
research studies, basic research disease-affiliated banks,
and clinical trial-biobanks. An escalating demand for
biospecimens is resulting in the transformation of
biobanking from an immature 'cottage industry' con-
ducted by individuals, into a complex institutional activ-
ity [5,6]. Biobanking has expanded to embrace a range of
specialized components including frameworks (ethics,
privacy, security), equipment (processing, annotation,
storage), operating procedures (biospecimen accrual,
processing, annotation, storage, release, distribution,
tracking), clinical informatics (pathology, treatment, and
outcome data), database structures (donor consent and
preference lists, inventory management tools, query
tools), policies (priorities and access processes), eco-
nomic models (funding sources, user fees, intellectual
property), governance models (for strategy and opera-
tions), and personnel with specialized roles and training.
This has meant that research biobanking, which was once
an activity mostly limited to clinical pathology, has now
evolved largely outside clinical departments as a research
discipline. This maturation is also exemplified by the pub-
lication of 'Best Practices' by a number of groups [7-10] as
well as the development of biobank data infrastructures
and common data elements [11-13].
Bottlenecks in Biobanking
Despite the advances of biobanking described above, sig-
nificant issues and limitations remain that are restricting
the impact of translational research. The major issues
include the need to increase the quality and standardiza-
tion of biospecimens collected, to enhance accrual capac-
ity in terms of scale and disease representation, and above
all, to maintain public trust in these activities. UnderlyingJournal of Translational Medicine 2009, 7:95 http://www.translational-medicine.com/content/7/1/95
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these issues is the need to ensure sustainability of
biobanks and to provide mechanisms for equitable and
appropriate access to biospecimens.
Quality issues relate to the complications inherent in
imposing complex research collection protocols on the
routine workflow of distinct clinical organizations. These
issues also relate to the difficulty in striking the right bal-
ance and appropriate division of biospecimens for both
clinical and research requirements ('tissue ethics'). In par-
ticular this division makes it difficult to ensure that repre-
sentative components of the biospecimens exist in both
collections. One example of this difficulty is the low fre-
quency with which pre-cancer lesions are captured in
research biobanks. Variations between biobanks also
influence quality. Even with recent advancement in the
way biobanking is conducted, the impact of pre-analytical
biospecimen variables, such as collection time [14], is not
typically accounted for in translational research.
Capacity issues relate to both geographical and temporal
gaps in the biobanking process. The geographic gap occurs
because research biobanks have typically developed in
health centres with an active research focus, not necessar-
ily those with the highest volume or diversity of surgical
and pathology services. Temporal capacity gaps arise
because treatment occurs independently of opportunities
to engage patients in research. Most biospecimens arise in
the course of clinical treatment at a single location and is
often completed before the relevance of the biospecimen
to research becomes apparent, diminishing the opportu-
nity to harvest biospecimens using specialized research
protocols. One example is the patient who chooses to
enroll in a clinical cancer therapy trial and has a formalin-
fixed paraffin-embedded (FFPE) block created for the clin-
ical archive. The retrieval of the FFPE archival block for a
future biomarker assay is often a significant logistic barrier
because it has been consigned to the clinical archive sev-
eral weeks before the patient chooses to become involved
in research. Studies requiring a frozen biospecimen are
often impossible because retaining a frozen biospecimen
is frequently not part of the standard clinical protocol.
Framework issues include inconsistent ethical frame-
works, privacy protection efforts and different "business
models" between biobanks [15-18]. These issues create
uncertainty around accountability to oversight bodies
(e.g., ethics boards, privacy offices, and funding agencies)
and to the public. This is of particular concern to those
who donate their tissue and data to biobanks. These
donors have the expectation that their donation will be
appropriately, equitably, and maximally utilized to
achieve better health care. Events relating to biobanking
in the UK provide concrete examples of the effect of failing
to address these issues[19,20]. As an activity that spans
and directly engages health care, research, and a subset of
society, it is essential for biobanking to communicate with
these stakeholders and the public at large.
Sustainability issues stem from the nature of funding; the
limited scale and the non-systematic resources dedicated
to biobanking [21]. It has been the expectation that
research biobanks should be able to conform to the busi-
ness models of other core research technology platforms.
Funding for core platforms is typically dependent on local
research strengths, dispersed over short durations, and
anticipates short-term sustainability or profit. This is
clearly at odds with the need to annotate samples with
extended outcome information over many years during
which clinical practice and research questions evolve to
determine the use of specific samples. It is also at odds
with the fundamental nature of biospecimens as gifts
from generous donors for research. Cost recovery strate-
gies for biospecimen retrieval, processing, and appropri-
ate annotation are emerging but are difficult to deploy in
such a way that ensures biobanks are self-sustainable.
Thus, ongoing costs of biobanking need to be addressed
as this is now an essential component of research transla-
tion.
Access issues around biospecimens and their use are seen
differently from the perspectives of donors, biobanks, and
research users. For donors, it often means having the
opportunity to contribute their biospecimen and health
data to drive research that can address their specific dis-
ease. For biobanks, it means access to potential donors to
seek their consent to accrue biospecimens. For research
users, it means finding and obtaining the right biospeci-
mens within biobanks and navigating regulatory and
oversight processes. Both donors and biobanks face the
geographical restrictions noted above, wherein the oppor-
tunity to connect and to donate is unavailable due to lack
of a formal biobank at the potential donors' health treat-
ment centre. A final issue that contributes to this barrier is
the currently pervasive, pre-operative approach/consent
paradigm which limits the opportunities for patients to
donate to biobanks.
General Solutions for Biobanking
One solution to address the issues of standardization of
quality and capacity is to create networks of biobanks.
This idea has stimulated initiatives and networks at
regional and national levels including the Canadian
Tumour Repository Network [22], CaBIG (cancer Bio-
medical Informatics Grid) and OBBR (Office of Biorepos-
itories and Biospecimen Research) in the USA [12,23],
OnCore in the UK [24], CNIO (Spanish National Cancer
Research Centre) in Spain [25], and Biobanking and Bio-
molecular Resources Research Infrastructure (BBMRI) in
Europe [26]. Networks enhance biospecimen and dataJournal of Translational Medicine 2009, 7:95 http://www.translational-medicine.com/content/7/1/95
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standards as well as awareness and access by research ini-
tiatives [27]. However, networks and associations of
biobanks constitute a 'top-down' approach. They do not
address local biobanking issues and the geographic and
temporal gaps noted above that are critical for quality and
capacity in biospecimen and data accrual.
A complimentary strategic solution to networks and asso-
ciations of biobanks is a 'bottom-up' approach to connect
donors and biobanks more effectively. Improved connec-
tion between donors and biobanks requires development
of processes within health systems to enable potential
donors to be referred to biobanks. Currently, many
patients are not offered the opportunity to donate to
research biobanks despite evidence, including consent
rates and donor feedback, demonstrating that this is desir-
able and beneficial to patients [28]. Although most
biobanks do not offer any direct health benefits to the
donor, there is thought to be a psychological benefit and
a sense of empowerment from donating biospecimens
and data to aid scientific and medical advancement [17].
Improvement in the donor-biobank connection requires
specific tools to enable donors to register their ongoing
status (e.g., disease recurrence and long-term treatment
toxicities) and preferences with biobanks. Underlying this
is the need for improved connection with the public
around the overall activity of biobanking. In the last five
years, public awareness of biobanking has grown to the
point that it has been ranked as a discipline amongst the
top 10 most important ideas that are changing the world
[29]. But the public has also been informed that there are
associated risks and perils [30], thus progress in biobank-
ing requires public engagement around the governance of
the discipline [31].
Improved connections between biospecimens and
biobanks requires development of processes to allow
biospecimen collection to be conducted in a standardized
fashion, responsive to research protocols, and within lim-
its independent of the timing of research consent relative
to the time of surgery or therapeutic procedure. This
would require re-integration of the biospecimen accrual
component of research biobanking into clinical pathol-
ogy. At the same time, the clinical discipline of pathology
needs to adopt processes for maintaining its clinical
archives to support the drive to achieve personalized med-
icine. Assessment of biomarkers are essential for this drive
and this is changing the value of the clinical archive from
a reference library to a 'real-time' clinical tool [32-35].
Ultimately it might be argued that repatriation of much of
current research biobanking to clinical pathology is the
best long term approach. This would maintain biospeci-
mens as a valuable resource located within the appropri-
ate privacy environment, facilitate accrual, clinical and
histological annotation, and enable appropriate triage for
clinical or research purposes to be made on an ongoing
basis.
The BC BioLibrary solution for biobanking
The British Columbia (BC) BioLibrary http://www.bcbi
olibrary.ca is a 'bottom-up' solution and was designed to
address issues discussed above. It arose from the desire of
a provincial health research foundation (the Michael
Smith Foundation for Health Research) to create trans-
formative health research infrastructure to enhance the
national and international competitiveness of BC's health
research community. A library is defined as a collection of
materials organized to provide physical, bibliographic
and intellectual access to a target group, with a staff that is
trained to provide services and programs related to the
information needs of the target group. Thus, a 'biolibrary'
is defined as a collection framework that provides all
forms of biobanks and their users (translational research-
ers) with access to human biospecimens. A biolibrary dif-
fers from a biobank in that its primary focus is limited to
acquisition, cataloguing, and distribution of biospeci-
mens to biobanks (Figure 1). In contrast, a biobank spe-
cializes in its capability for biospecimen processing,
annotation with histological and donor health data, and
long-term storage.
Methods
Development of the BC BioLibrary
The BC BioLibrary is a framework which consists of 3
main components: 1) 'Biospecimen Collection Units',
established within clinical pathology departments; 2)
patient/donor and biobank/user connections and engage-
ment through hospital referral processes and web-based
consent and inventory catalogues; and 3) public delibera-
tion to guide its governance. The framework also includes
several planned support components including a
'Biospecimen Distribution Unit'. The complete frame-
work as envisaged is described below, followed by the cur-
rent development status.
Biospecimen Collection Units
The Biospecimen Collection Units (BCUs) embedded
within pathology departments comprise trained biospeci-
men acquisition personnel (BCU Coordinators) super-
vised by the appropriate clinical leader within each
pathology department. Training provided by the BC
BioLibrary and its collection of standard operating proce-
dures extends the skills of pathologists' assistants and
technologists with further knowledge surrounding
biobanking, research requirements, protocols, ethics and
privacy issues. The BCU facilitates the triage of biospeci-
mens into multiple formats, including formalin-fixed par-
affin-embedded tissue blocks, flash frozen or OCT-frozen
material. Collected biospecimens are held in short term
storage and catalogued by logging a unique BC BioLibraryJournal of Translational Medicine 2009, 7:95 http://www.translational-medicine.com/content/7/1/95
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identification number into the relevant clinical pathology
record. Elements of this record are extracted into the BCU
inventory database (the 'BCU Catalogue').
Patient/Donor and Biobank Connection
The consent process relating to biospecimen use for
research has traditionally involved three distinct steps -
permission to contact, the preliminary interview to ascer-
tain interest and preferred medium for detailed discus-
sion, and the informed consent discussion and agreement
itself. The BC BioLibrary, acting as an 'honest broker' ena-
bles the key first step, by instituting a process to obtain
consent after the surgery or therapeutic procedure ('post-
operative consent protocol'). The BCU enables patholo-
gists to routinely harvest and hold portions of biospeci-
mens for research, in parallel with the portions of
biospecimens sampled and assessed for clinical diagnosis.
Once diagnosis has been completed and any immediate
diagnostic need for these portions has expired, the con-
sent status and potential research destiny of these research
biospecimens can be determined. The BCU facilitates the
contact step by communicating with the responsible clini-
cian (the surgeon or their designate such as the medical
office assistant) once a potential biospecimen has been
harvested, to ascertain if the patient/potential donor will
provide permission for contact. If permission is granted,
the BCU can forward the referral to the relevant, REB-
approved biobank. The biobank can then deploy its own
consent protocol or request this service from the BC BioLi-
brary consent office. Following completion of the consent
process, the biobank notifies the BCU Coordinator of the
consent status for any biospecimens that have been col-
lected.
The status of the biospecimen with respect to the potential
donor's specific research interests may already be known
through a pre-operative consent process, at the time of
harvesting. In this instance the BCU can distribute directly
to a specific biobank. If consent has been withheld by the
patient the research biospecimen is not collected or is
destroyed once this patient decision is known. Alterna-
tively, if the patient has not been approached pre-opera-
tively by a biobank, the biospecimen can be collected held
by the BCU for a defined period under an approved post-
op consent protocol, before its ability to be used for
research is determined. If at the end of the defined period,
the consent decision is unknown (e.g., due to inability to
make contact with the patient), the biospecimen and all
The BC BioLibrary and its components Figure 1
The BC BioLibrary and its components. The BC BioLibrary is a framework that lies upstream from biobanks in the cycle 
that begins and ends with people and leads to their better health. Specifically addressing the aspects of biobanking that involve 
collection and processing of biospecimens, the components include: 1) the Biospecimen Collection Units which are embedded 
in the hospital pathology departments and facilitates research orientated biospecimen processing by trained personnel using 
SOPs; 2) data management infrastructures which enable integration of consent information provided to biobanks with biospec-
imens from patient donors; and 3) public engagement processes to allow informed deliberation and input from the public into 
the governance of biobanking.
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related data are irreversibly anonymized (Figure 2). These
anonymized biospecimens may then be distributed to
REB-approved biobanks.
Biospecimen and Biobank Connection through Web-based 
Consent and Inventory Catalogues
Another key component of the BC BioLibrary is the devel-
opment of an improved linkage between biospecimens
and biobanks via web-based catalogues of existing
biospecimens (the 'Biospecimen Inventory Catalogue')
and consents (the 'Consent Catalogue').
The Biospecimen Inventory Catalogue component is
designed to provide a list of all biospecimens in short-
term storage across different BCUs. This component is still
under development. It is envisaged that it will be a search-
able database for existing biospecimens that are available
for distribution from the BCUs or alternatively from
biobanks in the community that have an established REB-
approved process for request and distribution of their
biospecimens. The information available in this database
will contain completely anonymized data: the BC BioLi-
brary ID, donor's age at the time of biospecimen collec-
The possible status of biospecimens collected by the BC BioLibrary BCU, as determined by the consent linked to the biospec- imen in relation to the time of surgery Figure 2
The possible status of biospecimens collected by the BC BioLibrary BCU, as determined by the consent linked 
to the biospecimen in relation to the time of surgery. The consent status of biospecimens collected and held by the 
BCU is influenced by two possible mechanisms for consent: #1) Pre-Operative Consent: If consent is secured pre-opera-
tively by a biobank then the biospecimen (green circle) is collected by the BCU and distributed to the biobank as a coded but 
identifiable biospecimen that can be linked to the patient donor clinical data by the biobank. #2) Post-Operative Consent: If 
consent is to be sought post-operatively then the biospecimen is collected by the BCU and held as an identifiable biospecimen 
(orange circle) for a period of up to 90 days (orange lines). During this time the consent status of the biospecimen may change 
and allow distribution to a biobank as follows: Accomplished - biospecimen (green circle) is distributed as per the procedure fol-
lowing a Pre-Operative Consent process. Not accomplished - the biospecimen (grey circle) and all related collection data is ano-
nymized and distributed to a biobank (if approved to receive such biospecimens) or destroyed Withheld - biospecimen (purple 
circle) and all related collection data is destroyed.
1) Pre-Operative Consent 2) Post-Operative Consent
90 day period
Anonymized Identifiable Anonymized
Biospecimen
Identifiable
Biospecimen #1
Consent:
Accomplished
#2
Consent:
Accomplished
Consent:
Not accomplished
#2
Ct
Biospecimen destroyed
Consent:
Withheld
Day 0 (Biospecimen collected) Day 90Journal of Translational Medicine 2009, 7:95 http://www.translational-medicine.com/content/7/1/95
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tion, donor's gender, type of biospecimen and disease
classification, and its location and availability. Data will
be linked to a request form directed to the BC BioLibrary
or to the biobank housing the biospecimen.
The Consent Catalogue component will be designed to
maintain lists which can be populated by each authenti-
cated, disease-focused biobank seeking access to biospec-
imens that are collected by the BCUs and that are derived
from donors enrolled into the biobank. Access to each list
within the Consent Catalogue is restricted to the originat-
ing biobank. The Consent Catalogue will be programmed
to establish a link between consented donors entered into
these lists and their corresponding biospecimens collected
in the BCUs. The mechanism for connecting donor con-
sent with the associated biospecimens will be by periodic
download of the Consent Catalogue as an encrypted file
to each BCU computer workstation. Using an unsuper-
vised query tool, the BCU inventory database will estab-
lish linkage between biospecimens at that BCU and
consented donors within the Consent Catalogue. All
matches will generate a flag in the BCU inventory data-
base as well as a report to enable classification of the
biospecimens collected to date by consent status. Based
on this report the BCU Coordinator will then destroy, dis-
tribute, or anonymize and then distribute biospecimens
to the appropriate biobank.
Public and Biobank Connection through Deliberation
Maintaining and improving public confidence is crucial to
the social sustainability of biobanking. Public trust is
associated with many topics: governance, clarity of mis-
sion and motivation, and transparency around issues of
funding and use for academic and industry applications.
The BC BioLibrary provides an attractive focus for input
from the public on all topics due to its broad scope and
direct focus on the primary intersection between patients
and biospecimen accrual. The BC BioLibrary has been
launched with an initial governance structure designed by
biobanking experts and under the external oversight of
ethics committees, privacy laws, and health research foun-
dations. However, the intention is to actively seek public
input into this structure and to evolve by integrating this
input into the oversight of biospecimen collection. Public
input is sought through a series of public consultation
events and based on a consensus building approach that
is fostered by deliberative democracy. The focus of these
events will evolve from discussion of general questions
around biobanking to more specific discussions around
the BC BioLibrary and biobanks and their associated gov-
ernance models.
Access to Biospecimens
Access to the BC BioLibrary requires scientific review (con-
ducted by a BC BioLibrary user access committee) to
determine priority of each user application and authenti-
cation including documentation of research ethics
approval (conducted by an institutional REB) to receive
and work with the human biospecimens requested.
Although still evolving as the BC BioLibrary expands from
single site pilot BCUs into a network, the BC BioLibrary
user access committee is envisaged to comprise represent-
atives from BCU sites and the BC BioLibrary management
and executive teams. The committee conducts scientific
peer review scaled to the request and logged through for-
mal applications to assign priority for access to BCUs and
seeks to ensure feasibility, fairness and accountability.
Single site requests are approved at the local BCU level by
the site director, site BCU Coordinator, and the BC BioLi-
brary manager. External and multi-site requests are han-
dled by the full BC BioLibrary access review committee.
All activities are reviewed by the BC BioLibrary Executive.
The BC BioLibrary creates a forum to seek resolutions of
competing requirements for biospecimens through peer
review and draws from collective experience in managing
access to biobanks. For those conflicts that persist, a bal-
anced consideration through peer review can help to rec-
ognize local priorities while also balancing these with
donor preferences and the scientific merit of different
projects. Most conflicts can be resolved by shared access,
division of the biospecimen, or staggered accrual periods
or sites. Another important aspect of user access involves
authentication of the users' scientific credentials and the
ethical and privacy considerations. REB review and
approval addresses these aspects and determines whether
access is restricted to biospecimens associated with
project-specific consent or can also include anonymized
biospecimens.
Distribution and Backup Storage for Biobanks
Each BCU currently transfers biospecimens direct to the
user, but once more BCUs are established, a single portal
for transfer and circulation of requested samples (e.g., a
centralized 'Biospecimen Distribution Unit') will be more
efficient. Users may also choose to receive processed
biospecimens and to utilize a range of services and
advanced analytical platforms available through the
Center for Translational and Advanced Genomics con-
nected to the BC BioLibrary [36]. Once distributed, the
ability to properly store and secure frozen biospecimens is
the responsibility of biobank users.
Results
To prepare for initial implementation of the BC BioLi-
brary plan, we began by delineating the functional com-
ponents required. A communications plan was developed
and a set of key messages derived to articulate compo-
nents as they related to five overarching goals. The mes-
sages were defined as follows: 1) the BC BioLibrary is a
facilitator, not a biobank; 2) the BC BioLibrary is intendedJournal of Translational Medicine 2009, 7:95 http://www.translational-medicine.com/content/7/1/95
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to help all interested BC researchers and educators; 3) the
BC BioLibrary helps pathologists streamline and improve
biobanking activities; 4) the BC BioLibrary enhances qual-
ity and accessibility of biospecimens; and 5) the BC BioLi-
brary contributes to the sustainability of biobanking in BC
by developing and upholding the public's trust. We pur-
sued this initial 'communication' effort in advance of
functional components to reduce the strong potential for
misinterpretation of the objectives and motivation under-
lying a new plan around biospecimen procurement from
the many established key stakeholders. The ongoing need
to correct the persistent assumption that biobanking can
continue as a 'cottage industry' and the misconception
that the BC BioLibrary exists to create a single 'BC
biobank' underscores the value of this approach.
Implementation began with the establishment of project
teams in 2007 to focus on the three main components of
the framework: standardization of biospecimens collec-
tion and processing ('Biospecimen Collection Unit and
Training' team, 13 members); enhanced communication
between the donors, biobanks ('Database and Informat-
ics' team, 7 members); and public engagement around
biobanking ('Public Engagement' team, 9 members).
These teams are managed by an Executive Committee (9
members) and the Management team (3 members), with
oversight provided by a Governance Oversight Commit-
tee (9 members). Through these teams and committees
the BC BioLibrary is driven by leaders in biobanking and
translational research across British Columbia, spanning
four major academic hospitals, three health authorities,
multiple affiliated academic institutions, and five major
institutional biobanks. The latter includes the BC Cancer
Agency Tumor Tissue Repository (TTR) program [37] and
the affiliated TTR Breast Bank, the Ovarian Cancer
Research Program of BC [38], the PROOF Centre of Excel-
lence [39], and the James Hogg iCAPTURE Centre[40], as
well as many other biobanks embedded within transla-
tional research groups.
Each element of the BC BioLibrary has been submitted for
REB approval in a stepwise fashion. The first two elements
involved establishing a website and a single, pilot BCU in
one pathology department. The website served to commu-
nicate with stakeholders around all aspects of biobanking
and the activities of the BC BioLibrary. Creation of the
pilot BCU was essential to provide a working prototype
around which we could engage with the REB and pathol-
ogy stakeholders. To date this first BCU has collected over
450 biospecimens in an 18 month period. Biospecimens
collected include those harvested from donors who pro-
vided pre-operative consent to two local studies, as well as
biospecimens collected under the post-operative consent
pilot and not linked to an identified study. The pilot BCU
has also been used to develop over 17 SOPs which detail
all aspects of biospecimen harvesting and data capture rel-
evant to the BCU, the BCU inventory database ('BCU Cat-
alogue'), as well as a web based training curriculum. The
evolution from this single, pilot BCU into a functional
accrual network has now begun with the recent establish-
ment of two additional pilot BCUs at additional hospital
sites and the graduation of the first pilot to a full BCU
approved and capable of supporting multiple biobank
users. The two additional web-based Catalogues (Biospec-
imen Inventory and Consent Catalogues) will be
deployed to complete the multi-site biospecimen acquisi-
tion capability of the BC BioLibrary.
An important element addressed by the BC BioLibrary is
the deployment of a system-wide post-operative consent
protocol. The protocol establishes a maximum time span
of 90 days from the time of surgery for holding a biospec-
imen in a BCU. This corresponds to the typical outside
limits of the period of completion of the diagnosis. This
duration optimally facilitates the necessary clinical proc-
ess for all biospecimens (pre-surgically consented or oth-
erwise) by enabling portions of the biospecimen to be
reclaimed and processed for clinical purposes if necessary
to complete the diagnosis. The parallel processes for
obtaining permission to contact, completing the consent
decision, and assigning consent status to the biospecimen
have also been delineated.
The construction of additional components of the frame-
work for centralized distribution has yet to begin. How-
ever as part of this planning process the BC BioLibrary
conducted a survey in 2008 to gauge the need for frozen
biospecimens by BC investigators. The results of this sur-
vey showed that over 80% of respondents (n = 55) indi-
cated they were not currently satisfied with their ability to
perform their research using biospecimens collected
through their own institution. Of those, 98% believed
they would benefit from access to biospecimens, with spe-
cific requirements for disease-specific (89%) and tissue-
specific (77%) biospecimens, collected from more than
one institution within the province. The full implementa-
tion of the BC BioLibrary BCUs would allow these needs
to be met. In addition a literature survey of over 3000
papers reported in cancer research journals at 5 year inter-
vals from 1988 to 2008 shows that use has increased 3
fold. The mean cohort size in research studies that utilized
tissue biospecimens has changed from approximately 50
to 150 over this period.
The final and key element addresses public trust. A public
engagement process has been launched with the first two
events held in 2007 and 2009. The design of these events,
the methodology and the composition of the participant
groups is described elsewhere [31]. Briefly, the first event
involved a diverse group of 25 members of the BC publicJournal of Translational Medicine 2009, 7:95 http://www.translational-medicine.com/content/7/1/95
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in an open-ended deliberation on biobanking. Partici-
pants were provided with access to information on
biobanks and then asked to discuss and share their
thoughts, concerns, and perspectives on biobanks. The
majority of participants agreed upon support for biobanks
in principle and the need for adequate governance of
biobanks [31]. The second event built on the first engage-
ment and sought specific input from the public on gov-
ernance, consent protocols, biospecimen collection, and
linkage to health information. In each area, specific ques-
tions were considered such as the best person, communi-
cation method, and timing for obtaining consent. The
outcomes are currently under analysis. The results from
the public engagement activities has strengthened our
interactions with the Research Ethics Board, physicians
and researchers as the public's wishes are in line with the
vision of the BC BioLibrary.
Discussion
Biobanking has historically focused on accrual and anno-
tation of biospecimens, but equally critical is the creation
of processes for engaging the public before accrual, dis-
tributing biospecimens, and cultivating inter-biobank col-
laborations. Further efforts towards fostering synergy
between the public and biobanks and associated proc-
esses will enhance scientific and technological advance-
ment and the translation of discovery to the clinic.
The BC BioLibrary is a novel, province-wide strategy
aimed at public engagement in biobanking, a common
framework for biospecimen acquisition embedded in
pathology departments, and integration of this frame-
work with existing biobanks and a spectrum of research
facilities. The design builds on evolutionary concepts
including the repatriation of biospecimen acquisition for
biobanks back into pathology departments and shared
governance of these processes.
As defined above, a 'biolibrary' differs from a biobank. A
biolibrary focuses on the complexities of connecting
donors with biobanks and on acquisition, cataloguing,
and distribution of biospecimens to biobanks. One com-
parable example of a biolibrary is the Cooperative Human
Tissue Network (CHTN) [41]. The program has developed
a prospective biospecimen collection system that is linked
to a wide variety of individual research and biobank
requests. This program is a highly successful framework
for support of basic research where the study questions
revolve principally around issues that do not require out-
come data. The BioLibrary also shares elements with the
Shared Pathology Informatics Network (SPIN) [42],
designed to enable indexing, annotation and retrieval of
biospecimens from clinical pathology archives to certified
research projects and investigators. In contrast to the
CHTN, this system and its concept was focused principally
on archival biospecimens. Both models share design ele-
ments with the BioLibrary that 'repatriate' components of
biobanking to clinical pathology.
Neither model directly accommodates the consent status
of the biospecimen. The CHTN was developed using the
non-specific surgical consent as a basis for distribution of
anonymized biospecimens with time-of-diagnosis anno-
tation. Both the CHTN and SPIN lack components to
effect public engagement. The BC BioLibrary builds on
these models to accommodate informed consent status of
biospecimens and enable a prospective connection
between a biospecimen, the donor's health record, and
prospective clinical treatment and outcome data. But per-
haps more importantly, the act of communication and the
transaction which leads to the approval to collect and
store a biospecimen linked to personal health data for
research purposes is critical to the future of biobanking.
An example of the acute effect on biobanking when public
confidence is lost was referred to above [19]. A substantial
effort directed at legal and regulatory reform was then
required to restore public and government trust and re-
enable continued investment in biobanking [20]. Exam-
ples of less obvious effects of denying patients the chance
to make choices and decisions, and with this the lost
opportunity to communicate with them around biobank-
ing, can be gleaned from the study of organ donation rates
in countries with opt-in and opt-out systems [43]. The BC
BioLibrary framework aims to maximize the opportuni-
ties for potential donors to be approached by biobanks for
informed consent to participate in research.
Although there is a growing body of evidence for the eth-
ical acceptability of post-operative consent process [44],
many biobanks' and their ethics committees have not yet
adopted this more attractive approach. By creating a
framework that can act as an honest broker, the BC BioLi-
brary facilitates deployment of a systematic post-operative
consent protocol. The BC BioLibrary can therefore over-
come geographic gaps for biobanks and facilitate donor
opportunities that would not otherwise be possible.
Current regulatory requirements for biobanking have
been developed to protect the interests of the public.
However, the implementation of regulations to address
privacy issues that were developed without biobanking in
mind [45] has required adaptation to biobanking proc-
esses and poses serious challenges to the pace of research
and financial burden to the researchers. At the same time,
it is not clear if the range of different interests or the prior-
ities of the public is well served by current regulatory
regimes. The establishment of a process of public involve-
ment in parallel with a new process for biospecimen
accrual has been essential in gaining trust from profes-
sional colleagues around issues such as the motivation ofJournal of Translational Medicine 2009, 7:95 http://www.translational-medicine.com/content/7/1/95
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the accrual network and in providing assurance to
Research Ethics Boards that the concept and operation of
the BioLibrary will be acceptable to the public. Public
input, fostered through deliberative democracy events,
will help us to devise trustworthy governance and to pro-
mote wider public understanding of biobanks [46]. Public
involvement will therefore contribute to the social sus-
tainability of the project.
Conclusion
The BC BioLibrary framework is designed to maximize the
opportunity and capability of injecting high quality, accu-
rately annotated biospecimens into all forms of biobanks.
This framework addresses geographical and temporal
issues that currently limit the capacity and capability of
biobanking. In the process, it provides improved opportu-
nity for oversight of biospecimen usage, standardization
of consent and collection processes, and equity in
biospecimen distribution to biobanks. Perhaps most
importantly, by creating a common shared infrastructure,
this framework reduces competition between biobanks
and offers a transparent process for donors to participate,
thereby enhancing public trust and providing an opportu-
nity for public involvement in designing optimal govern-
ance of biobanking.
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